The human immunodeficiency virus (HIV) evades the body’s immune defenses through multiple mutations, and antibodies produced by the host immune system against HIV follow complex and untraceable evolutionary pathways. This complexity makesRead More…
Immuno-Oncology Therapy (I-O) refers to a therapy that kills tumor cells by activating the body’s immune system. According to their different mechanisms of action, immunotherapeutic drugs can be divided into six categories.Read More…
In a recent study published in an international magazine of Immunity, scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancers’ defense againstRead More…
On May 17, 2018, the U.S. Food and Drug Administration approved erenumab-aooe (Aimovig) for the preventive treatment of migraine in adults. Erenumab is a human monoclonal antibody that targets calcitonin gene-related peptide (CGRP) receptor,Read More…
In the process of discovering monoclonal antibodies, after screening antibody libraries to obtain excellent candidate molecules that can specifically bind to targets, it is necessary to enhance certain pharmacological and other functionsRead More…
Most proteins have a tendency to form polymers, which are accompanied by slow polymer formation when they are produced, stored, transported, and injected into a patient. There are two reasons for whyRead More…
Monoclonal antibodies (mAbs) — preparations of a specific type of antibody designed to bind to a single target — have shown promise in the fight against cancer and autoimmune diseases. They alsoRead More…
Model of Factor VIII. © 3d ribbon/surface model of the human factor VIII after PDB 3CDZ. Ref.: Ngo JC, Huang M, Roth DA, Furie BC, Furie B (April 2008). DOI:10.1016/j.str.2008.03.001. Roche’s USRead More…
Great Achievements Have Been Made in Cancer Drug Listing In 2006-2017, a total of 89 oncology therapies (NTDs) were approved by the Center for Drug Evaluation and Research (CDER). The Biologics EvaluationRead More…
After more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine from targets development to technologies improvement. From clinical research to commercialization strategies,Read More…